Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700).
Despite extensive research efforts, effective therapies for refractive cancers have not yet been established, and development of successful treatment strategies remains the most important task in the field of oncology. We recently showed that AVE8062 (formerly AC7700), a derivative of combretastatin A-4, achieved irreversible stasis of tumor blood flow (TBF), thereby causing necrosis of tumor tissue by halting the supply of nutrients. Such effects were unrelated to cancer type. In this review, we summarize our experiments on antivascular and antitumor effects by AVE8062. We maintain that such starvation tactics against solid tumors constitute a new therapeutic strategy for all solid tumors, including refractory cancers.
Hori
Katsuyoshi
K
Department of Vascular Biology, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University, Seiryomachi, Sendai, Japan. k-hori@idac.tohoku.ac.jp
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008833:Microcirculation / Q000187:drug effects; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D051381:Rats; D012039:Regional Blood Flow / Q000187:drug effects; D012694:Serine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D013267:Stilbenes / Q000737:chemistry
D000970:Antineoplastic Agents; D013267:Stilbenes; D012694:Serine; C058728:fosbretabulin; C400245:AC 7700